vx680 and Body-Weight

Ligand efficiency (LE) and lipophilic efficiency (LipE) are two important indicators of "drug-likeness", which are dependent on the molecule's activity and physicochemical properties. We recently reported a furano-pyrimidine Aurora kinase inhibitor 4 (LE = 0.25; LipE = 1.75), with potent activity in vitro; however, 4 was inactive in vivo. On the basis of insights obtained from the X-ray co-crystal structure of the lead 4, various solubilizing functional groups were introduced to optimize both the activity and physicochemical properties. Emphasis was placed on identifying potential leads with improved activity as well as better LE and LipE by exercising tight control over the molecular weight and lipophilicity of the molecules. Rational optimization has led to the identification of Aurora kinase inhibitor 27 (IBPR001; LE = 0.26; LipE = 4.78), with improved in vitro potency and physicochemical properties, resulting in an in vivo active (HCT-116 colon cancer xenograft mouse model) anticancer agent.

Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Body Weight; Cell Proliferation; Crystallography, X-Ray; Drug Design; Furans; HCT116 Cells; Heterocyclic Compounds, 2-Ring; Humans; Ligands; Lipids; Male; Mice; Mice, Nude; Models, Chemical; Models, Molecular; Molecular Structure; Neoplasms; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Xenograft Model Antitumor Assays